Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | HCAR2 | Q8TDS4 | 4/20 | 0.45 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.45 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.45 |
| ▸ | HDAC7 | Q8WUI4 | 2/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.45 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.45 |
| ▸ | HDAC11 | Q96DB2 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.45 |
| ▸ | HDAC9 | Q9UKV0 | 2/20 | 0.45 |
| ▸ | HDAC5 | Q9UQL6 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.45 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.45 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.44 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.44 |
| ▸ | ITGAL | P20701 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4063251 | 1.00 | DAO (0.47) | DAOHCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL13851449 | 0.83 | GLA (0.46) | DAOHCAR2ALDH1A1MEN1LMNA | |
| SCHEMBL390357 | 0.77 | AKR1C3 (0.47) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9756924 | 0.77 | DAO (0.47) | DAOHCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL9756926 | 0.77 | DAO (0.47) | DAOHCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL390358 | 0.77 | AKR1C3 (0.47) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL9756825 | 0.73 | DAO (0.51) | DAOHCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL9756823 | 0.73 | DAO (0.51) | DAOHCAR2HDAC3HDAC4HDAC1 | |
| SCHEMBL8746677 | 0.71 | HCAR2 (0.64) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL8746675 | 0.71 | HCAR2 (0.64) | HCAR2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9095565-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140301975-A1 | Methods for Treating Blood Disorders | PHOENICIA BIOSCIENCES INC (US) | 2014-10-09 | — | — | US | disclosed |
| US-8759378-B2 | Methods for treating blood disorders | PHOENICIA BIOSCIENCES, INC. (US) | 2014-06-24 | — | — | US | disclosed |
| CN-101489544-A | Method for treating hematological disorders | HEMAQUEST PHARMACEUTICALS INC (US) | 2009-07-22 | — | — | CN | disclosed |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2009-05-28 | — | — | US | disclosed |
| EP-2023913-A2 | METHODS FOR TREATING BLOOD DISORDERS | Colorado State University Research Foundation (US) | 2009-02-18 | — | — | EP | disclosed |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | COLORADO STATE UNIVERSITY RESEARCH FOUNDATION | 2008-03-27 | — | — | US | disclosed |
| WO-2007133653-A2 | METHODS FOR TREATING BLOOD DISORDERS | HEMAQUEST PHARMACEUTICALS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140301975-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | DAO 1948/4885HCAR2 4439/4885HDAC3 1719/4885 |
| US-20090137567-A1 | Methods for Treating Blood Disorders | HBB, HBG1, HBG2 | DAO 1948/4885HCAR2 4439/4885HDAC3 1719/4885 |
| US-20080075692-A1 | prophylaxis of blood disorder such as sickle cell anemia, beta -thalassemia, neutropenia or thrombocytopenia, comprising administering carboxylic acids, that stimulates production of fetal hemoglobin, hematopoiesis, erythropoiesis, myelopoiesis and neutrophil production | HBG1, HBG2, HBB | DAO 1481/4885HCAR2 492/4885HDAC3 2651/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.